Danaher (DHR) PT Lowered to $275 at Leerink Partners

Go back to Danaher (DHR) PT Lowered to $275 at Leerink Partners

Danaher (DHR) PT Lowered to $277 at Baird

October 23, 2024 6:25 AM EDT

Baird analyst Catherine Schulte lowered the price target on Danaher (NYSE: DHR) to $277.00 (from $278.00) while maintaining a Outperform rating.

The analyst comments "Maintain Outperform rating, new $277 price target (-$1). DHR reported 3Q results ahead of expectations, driven by Biotechnology and Cepheid respiratory upside.... More

Danaher (DHR) PT Lowered to $275 at Barclays

October 23, 2024 2:58 AM EDT

Barclays analyst Luke Sergott lowered the price target on Danaher (NYSE: DHR) to $275.00 (from $285.00) while maintaining a Equalweight rating.... More

Danaher (DHR) Tops Q3 EPS by 14c; offers outlook

October 22, 2024 6:02 AM EDT

Danaher (NYSE: DHR) reported Q3 EPS of $1.71, $0.14 better than the analyst estimate of $1.57. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.59 billion.

OUTLOOK

Fourth Quarter and Full Year 2024 Outlook

The Company provides forecasted sales... More

Danaher (DHR) October 25 weekly call option implied volatility into quarter results

October 21, 2024 10:59 AM EDT

Danaher (NYSE: DHR) October 25 weekly call option implied volatility is at 59, November is at 32; compared to its 52-week range of 16 to 33; into the expected release of quarter results before the bell on October 22.

... More

Danaher (DHR) call put ratio 1.4 calls to 1 put into quarter results

October 21, 2024 5:35 AM EDT

Danaher (NYSE: DHR) October 25 weekly 275 straddle priced for a move of 5.5% into the expected release of quarter results before the bell on October 22. Call put ratio 1.4 calls to 1 put.

... More